Plus Therapeutics Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Plus Therapeutics, Inc. has officially implemented a 1-for-25 reverse stock split, effective April 2, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events

• Reverse Stock Split Effective

  The company's 1-for-25 reverse stock split became effective on April 2, 2026, with post-split trading commencing the same day.

• Nasdaq Compliance Driven

  The split aims to increase the per-share trading price to comply with The Nasdaq Capital Market's minimum $1.00 bid price requirement, addressing a previously identified delisting risk.

• Share Reduction and Dilution Headroom

  Outstanding shares were reduced from approximately 171.5 million to 6.86 million. However, the number of authorized shares was not reduced, significantly increasing the proportion of shares available for future issuance relative to outstanding shares.

• Fractional Share Treatment

  Stockholders who would otherwise be entitled to receive fractional shares will receive cash payments in lieu thereof.

auto_awesomeAnalysis

This reverse stock split is a critical step for Plus Therapeutics to maintain its listing on The Nasdaq Capital Market, addressing the previously disclosed risk of delisting due to low share price. While necessary for compliance, it does not resolve the company's underlying financial challenges, including the "going concern" doubt. The unchanged number of authorized shares, despite the significant reduction in outstanding shares, creates substantial headroom for future equity issuances, which could lead to significant dilution for existing shareholders. Investors should monitor the company's ability to sustain its share price above Nasdaq's minimum and its progress in addressing its financial viability.